Cargando…

Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials

Objective To systematically review the risk of mortality associated with long term use of tiotropium delivered using a mist inhaler for symptomatic improvement in chronic obstructive pulmonary disease. Data sources Medline, Embase, the pharmaceutical company clinical trials register, the US Food and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Sonal, Loke, Yoon K, Enright, Paul L, Furberg, Curt D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group Ltd. 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3114950/ https://www.ncbi.nlm.nih.gov/pubmed/21672999 http://dx.doi.org/10.1136/bmj.d3215

Ejemplares similares

An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease
por: Singh, Sonal, et al.
Publicado: (2010)

Effect of Tiotropium Soft Mist Inhalers on Dynamic Changes in Lung Mechanics of Patients with Chronic Obstructive Pulmonary Disease Receiving Mechanical Ventilation: A Prospective Pilot Study
por: Fu, Pin-Kuei, et al.
Publicado: (2020)

Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat(®) Soft Mist™ Inhaler in COPD
por: Hodder, Rick, et al.
Publicado: (2011)

Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat(®) Soft Mist(™) Inhaler
por: Hodder, Richard, et al.
Publicado: (2009)

Long-term safety of tiotropium delivered by Respimat(®) SoftMist™ Inhaler: patient selection and special considerations
por: Tan, Ching Kuo, et al.
Publicado: (2016)

Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease
por: Hohlfeld, JM, et al.
Publicado: (2014)

A dose-ranging study of tiotropium delivered via Respimat(®) Soft Mist(TM) Inhaler or HandiHaler(®) in COPD patients
por: Caillaud, Denis, et al.
Publicado: (2007)

A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter?
por: Dahl, Ronald, et al.
Publicado: (2016)

Technical Evaluation of Soft Mist Inhaler Use in Patients with Chronic Obstructive Pulmonary Disease: A Cross-Sectional Study
por: Zhang, Wei, et al.
Publicado: (2020)

The Combination of Tiotropium and Budesonide in the Treatment of Chronic Obstructive Pulmonary Disease
por: Um, Sang-Won, et al.
Publicado: (2007)

Tiotropium Bromide in Chronic Obstructive Pulmonary Disease and Bronchial Asthma
por: Alvarado-Gonzalez, Alcibey, et al.
Publicado: (2015)

A comparison of tiotropium/olodaterol vs tiotropium alone in terms of treatment effect for chronic obstructive pulmonary disease: A meta-analysis
por: He, Jie, et al.
Publicado: (2020)

TRONARTO: A Randomized, Placebo-Controlled Study of Tiotropium/Olodaterol Delivered via Soft Mist Inhaler in COPD Patients Stratified by Peak Inspiratory Flow
por: Mahler, Donald A, et al.
Publicado: (2021)

A comparison of tiotropium/olodaterol vs tiotropium alone in terms of treatment effect for chronic obstructive pulmonary disease: A meta-analysis: Retraction
Publicado: (2020)

Tiotropium Respimat® improves physical functioning in chronic obstructive pulmonary disease
por: Rau-Berger, Heike, et al.
Publicado: (2010)

Tiotropium in chronic obstructive pulmonary disease – a review of clinical development
por: Anzueto, Antonio, et al.
Publicado: (2020)

Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease
por: Ramadan, Wijdan H, et al.
Publicado: (2015)

Use of Respimat(®) Soft Mist™ Inhaler in COPD patients
por: Anderson, Paula
Publicado: (2006)

Evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease
por: Naik, Shalini, et al.
Publicado: (2010)

Outcomes associated with initiation of tiotropium or fluticasone/salmeterol in patients with chronic obstructive pulmonary disease
por: Halpern, Rachel, et al.
Publicado: (2011)

The Role of Tiotropium+Olodaterol Dual Bronchodilator Therapy in the Management of Chronic Obstructive Pulmonary Disease
por: Halpin, David M. G.
Publicado: (2018)

Tiotropium Bromide Attenuates Mucus Hypersecretion in Patients with Stable Chronic Obstructive Pulmonary Disease
por: Yu, Suyun, et al.
Publicado: (2021)

Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat(®) Inhaler in Patients with Chronic Obstructive Pulmonary Disease
por: Aalbers, René, et al.
Publicado: (2015)

Role of Tiotropium in Reducing Exacerbations of Chronic Obstructive Pulmonary Disease When Combined With Long‐Acting β (2)‐Agonists and Inhaled Corticosteroids: The OUTPUL Study
por: Ferroni, Eliana, et al.
Publicado: (2016)

Pharmacokinetics and tolerability (Study 1) with particular reference to ocular safety (Study 2) of tiotropium Respimat(®) Soft Mist(™) Inhaler: findings from two dose-ranging studies in healthy men
por: Feifel, Ulrich, et al.
Publicado: (2008)

Asthma patients prefer Respimat(®) Soft Mist™ Inhaler to Turbuhaler(®)
por: Hodder, Rick, et al.
Publicado: (2009)

Reducing carbon footprint by switching to reusable soft-mist inhalers
por: Janson, Christer, et al.
Publicado: (2023)

Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary disease
por: Chatterjee, Arjun, et al.
Publicado: (2012)

Effects of tiotropium on sympathetic activation during exercise in stable chronic obstructive pulmonary disease patients
por: Yoshimura, Kenji, et al.
Publicado: (2012)

Efficacy of budesonide/formoterol and tiotropium combination for the treatment of Chinese patients with chronic obstructive pulmonary disease
por: Feng, Jun-fei, et al.
Publicado: (2018)

Direct Switch from Tiotropium to Indacaterol/Glycopyrronium in Chronic Obstructive Pulmonary Disease Patients in Korea
por: Lee, Sang Haak, et al.
Publicado: (2021)

A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids
por: Vogelberg, Christian, et al.
Publicado: (2015)

Association between poor therapy adherence to inhaled corticosteroids and tiotropium and morbidity and mortality in patients with COPD
por: Koehorst-ter Huurne, Kirsten, et al.
Publicado: (2018)

Pharmacokinetic Study of Epinephrine Hydrofluoroalkane (Primatene MIST) Metered-Dose Inhaler
por: Kerwin, Edward M., et al.
Publicado: (2020)

The Respimat(®) Soft Mist Inhaler: Implications of Drug Delivery Characteristics for Patients
por: Iwanaga, Takashi, et al.
Publicado: (2019)

Questionnaire on switching from the tiotropium HandiHaler to the Respimat inhaler in patients with chronic obstructive pulmonary disease: changes in handling and preferences immediately and several years after the switch
por: Hanada, Soichiro, et al.
Publicado: (2015)

Skin reaction to inhaled tiotropium bromide: a case report
por: Incorvaia, Cristoforo, et al.
Publicado: (2011)

Quality of life and adherence to inhaled corticosteroids and tiotropium in COPD are related
por: Koehorst-ter Huurne, Kirsten, et al.
Publicado: (2016)

Pharmacokinetic characteristics of fluticasone, salmeterol and tiotropium after concurrent inhalation
por: Sunwoo, Jung, et al.
Publicado: (2017)

Clinical trial design in chronic obstructive pulmonary disease: current perspectives and considerations with regard to blinding of tiotropium
por: Beeh, Kai-Michael, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_r1t3h8srja7d2j8i1dmajs1vl0